, Volume 30, Issue 7, pp 551–564 | Cite as

Economic Evaluation of Smoking-Cessation Therapies

A Critical and Systematic Review of Simulation Models
  • Kristian Bolin
Systematic Review



Smoking is probably the most important among preventable health risks. Health economic evaluation of smoking-cessation interventions, applying a lifetime perspective, is made possible by available epidemiological knowledge. The well established method of performing cost-effectiveness analyses of smoking-cessation interventions involves mathematical modelling (both deterministic and stochastic) of future events important for cost effectiveness.


This study surveys cost-effectiveness analyses of smoking cessation, with a particular focus on the mathematical modelling and simulation analyses performed.

Data Sources

A systematic literature search was performed using the databases MEDLINE, Econlit and Academic Search Complete.

Study Selection

Health economic evaluations, published as full-length journal articles, were searched for.


423 studies were identified and 78 were finally included, of which 30 were assessed as being highly relevant, based on the application of simulation modelling.


In general, studies are well performed as regards modelling. Common weaknesses include reporting of modelling details; validation of used simulation models; and the handling of structural uncertainty and different types of heterogeneity.


Smoking Cessation Sickness Absenteeism Nicotine Replacement Therapy Varenicline Health Economic Evaluation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



No sources of funding were used to prepare this article. The author has no conflicts of interest that are directly relevant to its content and the opinions expressed are the author’s own.

Supplementary material

40273_2012_30070551_MOESM1_ESM.pdf (224 kb)
Supplementary material, approximately 229 KB.
40273_2012_30070551_MOESM2_ESM.pdf (497 kb)
Supplementary material, approximately 509 KB.
40273_2012_30070551_MOESM3_ESM.pdf (597 kb)
Supplementary material, approximately 611 KB.


  1. 1.
    Wynder EL, Graham EA. Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma: a study of 684 proved cases. JAMA 1950; 143: 329–96CrossRefGoogle Scholar
  2. 2.
    Doll R, Hill AB. The mortality of doctors in relation to their smoking habits: a preliminary report. BMJ 1954; 1: 1451–5CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Doll R, Hill AB. Lung cancer and other causes of death in relation to smoking: a second report on the mortality of British doctors. BMJ 1956; 2: 1071–81CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Hammond ED, Horn D. Smoking and death rates — report on forty-four months of follow-up on 187,783 men: I. Total mortality. JAMA 1958; 166: 1159–72CrossRefGoogle Scholar
  5. 5.
    Hammond ED, Horn D. Smoking and death rates — report on forty-four months of follow-up on 187,783 men: II. Death rates by cause. JAMA 1958; 166: 1294–308CrossRefGoogle Scholar
  6. 6.
    Royal College of Physicians. Smoking and health: summary and report of the Royal College of Physicians of London on smoking in relation to cancer of the lung and other diseases. New York: Pitman Publishing, 1962Google Scholar
  7. 7.
    U.S. Department of Health, Education, and Welfare. Smoking and health: report to the Advisory Committee to the Surgeon General of the Public Health Service. Washington, DC: U.S. Government Printing Office, 1964. PHS publication no.: 1103Google Scholar
  8. 8.
    World Health Organization. Tobacco or health: a global status report. Geneva: WHO, 1997Google Scholar
  9. 9.
    Fagerström K. The epidemiology of smoking: health consequences and benefits of cessation. Drugs 2002; 62 Suppl. 2: 1–9CrossRefPubMedGoogle Scholar
  10. 10.
    Shafey O, Dolwick S, Guindon GE, editors. Tobacco control country profiles. 2nd rev. ed. Atlanta (GA): American Cancer Society, 2003Google Scholar
  11. 11.
    Abrams DB, Graham AL, Levy DT, et al. Boosting population quits through evidence-based cessation treatment and policy. Am J Prev Med 2010 Mar; 38 (3 Suppl.): S351–63CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Hughes JR. How confident should we be that smoking cessation treatments work? Addiction 2009; 104 (10): 1637–40CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Thun MJ, Apicella LF, Henley SJ. Smoking vs other risk factors as the cause of smoking-attributable deaths: confounding in the courtroom. JAMA 2000; 284: 706–12CrossRefPubMedGoogle Scholar
  14. 14.
    Woolacott NF, Jones L, Forbes CA, et al. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. Health Technol Assess 2002; 6 (16): 1–245CrossRefGoogle Scholar
  15. 15.
    Keating GM, Lyseng-Williamson KA. Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation. Pharmacoeconomics 2010; 28 (3): 231–54CrossRefPubMedGoogle Scholar
  16. 16.
    Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ 2006; 15 (12): 1295–310CrossRefPubMedGoogle Scholar
  17. 17.
    Philips Z, Bojke L, Sculpher M, et al. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics 2006; 24 (4): 355–71CrossRefPubMedGoogle Scholar
  18. 18.
    Elixhauser A. The costs of smoking and the cost effectiveness of smoking-cessation programs. J Public Health Policy 1990; 11 (2): 218–37CrossRefPubMedGoogle Scholar
  19. 19.
    Song F, Raftery J, Aveyard P, et al. Cost-effectiveness of pharmacological interventions for smoking cessation: a literature review and a decision analytic analysis. Med Decis Making 2002; 22 (5 Suppl.): S26–37CrossRefPubMedGoogle Scholar
  20. 20.
    Ronckers ET, Groot W, Ament AJ. Systematic review of economic evaluations of smoking cessation: standardizing the cost-effectiveness. Med Decis Making 2005; 25 (4): 437–48CrossRefPubMedGoogle Scholar
  21. 21.
    Orme ME, Susan LH, Kennedy LM, et al. Development of the health and economic consequences of smoking interactive model. Tob Control 2001; 10: 55–6CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Gunning-Schepers LJ. The health benefits of prevention: a simulation approach. Health Policy 1989; 12: 1–256PubMedGoogle Scholar
  23. 23.
    Wetter D, Cofta-Gunn L, Fouladi R, et al. Late relapse/sustained abstinence among former smokers: a longitudinal study. Prev Med 2004; 39: 1556–63CrossRefGoogle Scholar
  24. 24.
    Krall E, Garvey A, Garcia R. Smoking relapse after 2 years of abstinence: findings from the VA Normative Aging Study. Nicotine Tob Res 2002; 4: 95–100CrossRefPubMedGoogle Scholar
  25. 25.
    Hoogenveen RT, de Hollander AEM, van Genugten MLL. The chronic disease modeling approach. Bilthoven: National Institute of Public Health and the Environment (RIVM), 1998Google Scholar
  26. 26.
    Brønnum-Hansen H. How good is the Prevent model for estimating the health benefits of prevention? J Epidemiol Community Health 1999; 53 (5): 300–5CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Prevent [computer program]. Version 3.01. Wilston (QLD): EpiGear International, 2009 [online]. Available from URL: [Accessed 2011 Feb 5]
  28. 28.
    Hoogenveen RT, van Baal PHM, Boshuizen HC. Chronic disease projections in heterogeneous ageing populations: approximating multi-state models of joint distributions by modeling marginal distributions. Math Med Biol 2010; 27: 1–19CrossRefPubMedGoogle Scholar
  29. 29.
    Hurley SF, Matthews JP. The Quit Benefits Model: a Markov model for assessing the health benefits and health care cost savings of quitting smoking. Cost Eff Resour Alloc 2007; 5: 2–20CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Tengs TO, Ahmad S, Savage JM, et al. The AMA proposal to mandate nicotine reduction in cigarettes: a simulation of the population health impacts. Prev Med 2005; 40: 170–80CrossRefPubMedGoogle Scholar
  31. 31.
    Tengs T, Ahmad S, Moore R, et al. Federal policy mandating safer cigarettes: a hypothetical simulation of the anticipated population health gains or losses. J Policy Anal Manage 2004; 3: 857–72CrossRefGoogle Scholar
  32. 32.
    Igarashi A, Takuma H, Fukuda T, et al. Cost-utility analysis of varenicline, an oral smoking-cessation drug, in Japan. Pharmacoeconomics 2009; 27 (3): 247–61CrossRefPubMedGoogle Scholar
  33. 33.
    Thavorn K, Chaiyakunapruk N. A cost-effectiveness analysis of a community pharmacist-based smoking cessation programme in Thailand. Tob Control 2008; 17 (3): 177–82CrossRefPubMedGoogle Scholar
  34. 34.
    Dino G, Horn K, Abdulkadri A, et al. Cost-effectiveness analysis of the Not On Tobacco program for adolescent smoking cessation. Prev Sci 2008; 9 (1): 38–46CrossRefPubMedGoogle Scholar
  35. 35.
    Welton NJ, Johnstone EC, David SP, et al. A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation. Nicotine Tob Res 2008; 10 (1): 231–40CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Hurley SF, Matthews JP, Guymer RH. Cost-effectiveness of smoking cessation to prevent age-related macular degeneration. Cost Eff Resour Alloc 2008; 6: 18CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Bertram MY, Lim SS, Wallace AL, et al. Costs and benefits of smoking cessation aids: making a case for public reimbursement of nicotine replacement therapy in Australia. Tob Control 2007; 16 (4): 255–60CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Olsen KR, Bilde L, Juhl HH, et al. Cost-effectiveness of the Danish smoking cessation interventions: subgroup analysis based on the Danish Smoking Cessation Database. Eur J Health Econ 2006; 7 (4): 255–64CrossRefPubMedGoogle Scholar
  39. 39.
    Cornuz J, Gilbert A, Pinget C, et al. Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparison. Tob Control 2006; 15(3): 152–9CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Cornuz J, Pinget C, Gilbert A, et al. Cost-effectiveness analysis of the first-line therapies for nicotine dependence. Eur J Clin Pharmacol 2003; 59 (3): 201–6CrossRefPubMedGoogle Scholar
  41. 41.
    Fiscella K, Franks P. Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians’ smoking cessation counseling. JAMA 1996; 275 (16): 1247–51CrossRefPubMedGoogle Scholar
  42. 42.
    Parrott S, Godfrey C, Raw M, et al. Guidance for commissioners on the cost effectiveness of smoking cessation interventions: health educational authority. Thorax 1998; 53 Suppl. 5: 1–38Google Scholar
  43. 43.
    Ratcliffe J, Cairns J, Platt S. Cost effectiveness of a mass media-led anti-smoking campaign in Scotland. Tob Control 1997; 6 (2): 104–10CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Vemer P, Rutten-van Mölken M, Kaper J, et al. If you try to stop smoking, should we pay for it? The cost-utility of reimbursing smoking cessation support in the Netherlands. Addiction 2010; 105 (6): 1088–97CrossRefPubMedGoogle Scholar
  45. 45.
    Feenstra TL, Hamberg-van Reenen HH, Hoogenveen RT, et al. Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study. Value Health 2005; 8 (3): 178–90CrossRefPubMedGoogle Scholar
  46. 46.
    Hurley SF, Matthews JP. Cost-effectiveness of the Australian National Tobacco Campaign. Tob Control 2008; 17 (6): 379–84CrossRefPubMedGoogle Scholar
  47. 47.
    Bae JY, Kim CH, Lee EK. Evaluation of cost-utility of varenicline compared with existing smoking cessation therapies in South Korea. Value Health 2009; 12 Suppl. 3: S70–3CrossRefPubMedGoogle Scholar
  48. 48.
    Bolin K, Mörk AC, Wilson K. Smoking-cessation therapy using varenicline: the cost-utility of an additional 12-week course of varenicline for the maintenance of smoking abstinence. J Eval Clin Pract 2009; 15 (3): 478–85CrossRefPubMedGoogle Scholar
  49. 49.
    Bolin K, Mörk AC, Willers S, et al. Varenicline as compared to bupropion in smoking cessation therapy: cost-utility results for Sweden. Respir Med 2008; 102 (5): 699–710CrossRefPubMedGoogle Scholar
  50. 50.
    Bolin K, Lindgren B, Willers S. The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden. Chest 2006; 129 (3): 651–60CrossRefPubMedGoogle Scholar
  51. 51.
    Johansson PM, Tillgren PE, Guldbrandsson KA, et al. A model for cost-effectiveness analyses of smoking cessation interventions applied to a Quit-and-Win contest for mothers of small children. Scand J Public Health 2005; 33 (5): 343–52CrossRefPubMedGoogle Scholar
  52. 52.
    Halpern MT, Khan ZM, Young TL, et al. Economic model of sustained-release bupropion hydrochloride in health plan and work site smoking-cessation programs. Am J Health Syst Pharm 2000; 57 (15): 1421–9PubMedGoogle Scholar
  53. 53.
    Heitjan DF, Asch DA, Ray R, et al. Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment. Pharmacogenomics J 2008; 8 (6): 391–9CrossRefPubMedGoogle Scholar
  54. 54.
    Bolin K, Wilson K, Benhaddi H, et al. Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation: results from four European countries. Eur J Public Health 2009; 19 (6): 650–4CrossRefPubMedGoogle Scholar
  55. 55.
    Vemer P, Rutten-van Mölken M. Crossing borders: factors affecting differences in cost-effectiveness of smoking cessation interventions between European countries. Value Health 2010; 13 (2): 230–41CrossRefPubMedGoogle Scholar
  56. 56.
    Knight C, Howard P, Baker CL, et al. The cost-effectiveness of an extended course (12+12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: an extension and update to the BENESCO Model. Value Health 2010; 13 (2): 209–14CrossRefPubMedGoogle Scholar
  57. 57.
    Linden K, Jormanainen V, Linna M, et al. Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers. Curr Med Res Opin 2010; 26 (3): 549–60CrossRefPubMedGoogle Scholar
  58. 58.
    Annemans L, Nackaerts K, Bartsch P, et al. Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation. Clin Drug Investig 2009; 29 (10): 655–65CrossRefPubMedGoogle Scholar
  59. 59.
    Hoogendoorn M, Welsing P, Rutten-van Mölken MP. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. Curr Med Res Opin 2008; 24 (1): 51–61CrossRefPubMedGoogle Scholar
  60. 60.
    Tengs TO, Osgood ND, Chen LL. The cost-effectiveness of intensive national school-based anti-tobacco education: results from the Tobacco Policy Model. Prev Med 2001; 33: 558–70CrossRefPubMedGoogle Scholar
  61. 61.
    Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 1997; 16: 33–64CrossRefPubMedGoogle Scholar
  62. 62.
    Lundin D, Ramsberg J. On survival consumption costs: a reply to Nyman. Health Econ 2008; 17 (2) 293–7CrossRefPubMedGoogle Scholar
  63. 63.
    Nyman JA. Should the consumption of survivors be included as a cost in cost-utility analysis? Health Econ 2004; 13: 417–27CrossRefPubMedGoogle Scholar
  64. 64.
    Nyman JA. More on survival consumption costs in cost-utility analysis. Health Econ 2006; 15: 319–22CrossRefGoogle Scholar
  65. 65.
    Howard P, Knight C, Boler A, et al. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO simulation model: application to a population of US adult smokers. Pharmacoeconomics 2008; 26 (6): 497–511CrossRefPubMedGoogle Scholar
  66. 66.
    Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press, 2006Google Scholar

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  1. 1.Department of EconomicsLund UniversityLundSweden

Personalised recommendations